Hutchison China Meditech Limited Chi-Med to Present at JP Morgan Conference

TIDMHCM

Hutchison China Meditech Limited

06 January 2020

Press Release

Chi-Med to Present at the 38(th) Annual JP Morgan Healthcare Conference

London: Monday, January 6, 2020: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today announces that Christian Hogg, Chief Executive Officer, will present at the 38(th) Annual JP Morgan Healthcare Conference on Wednesday, January 15, 2020 at 1:00pm PST in San Francisco, CA.

The presentation will be webcast live and can be accessed at www.chi-med.com in the Shareholder Information section under "Events, Circulars & Forms." Investors interested in listening to the live webcast should log on before the start time to download any software required. A replay of the event will be available shortly thereafter, for 90 days.

About Chi-Med

Chi-Med (AIM/Nasdaq: HCM) is an innovative biopharmaceutical company which researches, develops, manufactures and markets pharmaceutical products. Its Innovation Platform, Hutchison MediPharma, has about 490 scientists and staff focusing on discovering, developing and commercializing targeted therapeutics and immunotherapies in oncology and autoimmune diseases. It has a portfolio of eight cancer drug candidates currently in clinical studies around the world. Chi-Med's Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products, covering an extensive network of hospitals across China.

Chi-Med is headquartered in Hong Kong and is dual-listed on the AIM market of the London Stock Exchange and the Nasdaq Global Select Market. For more information, please visit: www.chi-med.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see Chi-Med's filings with the U.S. Securities and Exchange Commission and on AIM. Chi-Med undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.

CONTACTS

 
Investor Enquiries 
  Mark Lee, Senior Vice President                             +852 2121 8200 
  Annie Cheng, Vice President                                 +1 (973) 567 3786 
  David Dible, Citigate Dewe Rogerson                         +44 7967 566 919 (Mobile) 
                                                              david.dible@citigatedewerogerson.com 
  Xuan Yang, Solebury Trout                                   +1 (415) 971 9412 (Mobile) 
                                                               xyang@troutgroup.com 
 
Media Enquiries 
  UK & Europe - Anthony Carlisle, Citigate Dewe Rogerson      +44 7973 611 888 (Mobile) 
                                                               anthony.carlisle@cdrconsultancy.co.uk 
  Americas - Brad Miles, Solebury Trout                       +1 (917) 570 7340 (Mobile) 
                                                               bmiles@troutgroup.com 
  Hong Kong & Asia ex-China     - Joseph Chi Lo, Brunswick    +852 9850 5033 (Mobile) 
                                                               jlo@brunswickgroup.com 
                                - Zhou Yi, Brunswick          +852 9783 6894 (Mobile) 
                                                               yzhou@brunswickgroup.com 
  Mainland China - Sam Shen, Edelman                          +86 136 7179 1029 (Mobile) 
                                                               sam.shen@edelman.com 
 
Nominated Advisor 
  Atholl Tweedie, Panmure Gordon (UK) Limited                 +44 (20) 7886 2500

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

NRAKKABKOBKKKDK

(END) Dow Jones Newswires

January 06, 2020 02:04 ET (07:04 GMT)

Hutchison China Meditech (LSE:0J7G)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024